5 Cathie Wood Stocks that are on Sale Now

4. Senti Biosciences, Inc. (NASDAQ:SNTI)

Number of Hedge Fund Holders: 3
Year to Date Loss: 70%

Senti Biosciences, Inc. (NASDAQ:SNTI) is a preclinical biotechnology company that develops next-generation cell and gene therapies with gene circuit platform technologies. Its flagship product leverages allogeneic chimeric antigen receptor natural killer for various oncology indications. Currently, the stock is rated as a hold with $2 a share price target, implying a 365% upside potential from current levels.

After pulling the plug on its liver cancer candidate, the company’s sentiments took a significant hit early in the year. Senti Biosciences, Inc. (NASDAQ:SNTI) also announced plans to narrow it down to two CAR NK programs as it sought to preserve money. The stock has since shed nearly 70% in market value, dragging Woods funds lower.

According to Insider Monkey’s database of 910 hedge funds, 3 hedge funds have stakes in Senti Biosciences, Inc. (NASDAQ:SNTI) as of the end of the second quarter of 2023, up from 2 funds in the previous quarter.

Follow Senti Biosciences Inc.

[/company-follow-email]